Core Points - The company, Jinglan Technology Co., Ltd., has acknowledged accounting errors due to violations leading to inflated financial figures from 2018 to 2020 [1][2][4] - The company has made retrospective adjustments to its financial statements for the years 2020 and 2021, correcting inflated revenue and costs [2][3] - The adjustments resulted in a decrease of 16,291.03 million yuan in reported revenue for 2020, which was 14.06% of the disclosed revenue for that year [1][2] - The company has not made accounting adjustments for performance compensation related to unfulfilled profit commitments due to uncertainty in recoverability [4] Financial Statement Adjustments - For the 2020 consolidated balance sheet, adjustments included: - Contract assets decreased by 132,886,762.96 yuan to 2,940,657,649.19 yuan - Accounts payable decreased by 96,546,651.65 yuan to 1,743,811,151.80 yuan - Contract liabilities increased by 40,995,838.57 yuan to 613,379,042.15 yuan [2][3] - For the 2021 consolidated income statement, adjustments included: - Revenue decreased by 162,910,300.00 yuan to 995,410,211.62 yuan - Operating costs decreased by 96,546,651.65 yuan to 1,070,880,382.08 yuan - Income tax expenses decreased by 8,656,162.03 yuan to 41,103,694.41 yuan [3][4] Audit and Compliance - The company received a verification report from Zhongxing Cai Guanghua Accounting Firm, confirming that the adjustments comply with relevant accounting standards and accurately reflect the correction of prior accounting errors [4][5]

证券代码：002297 证券简称：博云新材 公告编号：2025-035 湖南博云新材料股份有限公司 关于持股 5%以上股东减持计划期限届满的公告 股东湖南湘投高科技创业投资有限公司保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 湖南博云新材料股份有限公司（以下简称"公司"）于 2025 年 5 月 13 日披 露了《关于持股 5%以上股东减持股份的预披露公告》（公告编号：2025-022）。 公司持股 5%以上股东湖南湘投高科技创业投资有限公司（以下简称"高创投"） 计划自公告披露之日起十五个交易日后的三个月内（2025 年 6 月 5 日至 2025 年 数倍的公告》（公告编号：2025-025） 近日，公司收到持股 5%以上股东高创投出具的《关于股份减持计划期限届 满的告知函》。截至本公告披露日，本次减持计划期限届满，高创投共计减持股 份 5,727,400 股，减持比例为 1%。现将有关情况公告如下： 一、股份减持情况 （一）高创投减持股份情况 | | | 成交均价（元/ | | 成交数量 | 减持比 ...

Transaction Overview - The company plans to acquire 50.6329% equity of Yiwang Juice Co., Ltd. for a total of RMB 26,917,521.60, with RMB 5,000,000 allocated to registered capital and RMB 21,917,521.60 to capital reserves [1][2][17] - After the transaction, Yiwang Juice will become a subsidiary of the company and included in the consolidated financial statements [2][27] Approval Process - The board of directors unanimously approved the acquisition proposal with no votes against or abstentions [2][27] - The transaction does not constitute a related party transaction or a major asset restructuring as per relevant regulations [2][27] Target Company Information - Yiwang Juice Co., Ltd. is a limited liability company with a registered capital of RMB 9,875,000, established on September 18, 2024 [7][14] - The company specializes in the research, production, and sales of concentrated apple juice [14][27] Financial Data of Target Company - As of June 30, 2025, Yiwang Juice reported total assets of RMB 56,633,700 and total liabilities of RMB 30,389,100, resulting in net assets of RMB 26,244,595.53 [14][16] - The company generated revenue of RMB 5,266,400 in Q4 2024 and RMB 5,160 in Q2 2025, with a net loss of RMB 221,770 in the first half of 2025 [14][15] Strategic Importance - The acquisition is a significant step in the company's strategic layout in the beverage industry, aiming to enhance supply chain integration and expand its business scale [27] - Yiwang Juice's established procurement and sales channels will strengthen the company's competitive position and profitability in the beverage sector [27]

证券代码：601838 证券简称：成都银行 公告编号：2025-053 成都银行股份有限公司 第八届董事会第十八次（临时）会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 成都银行股份有限公司（以下简称"本公司"）于 2025 年 9 月 4 日以电子邮件及书面方式向全体董事发出关于召开董事会会议的通 知和材料，本公司第八届董事会第十八次（临时）会议于 2025 年 9 月 4 日在本公司总部 5 楼 1 号会议室以现场结合视频方式召开。本次 会议应出席有表决权董事 11 名，徐登义、余力、马骁 3 名董事现场 出席，王永强、郭令海、付剑峰、马晓峰、陈存泰、龙文彬、顾培东、 余海宗 8 名董事通过视频连线方式参加会议。会议由副董事长、行长 徐登义主持。党委书记黄建军、丰隆银行提名董事人选张育鸣、4 名 监事以及本公司部分高级管理人员等列席会议。会议的召开符合《中 华人民共和国公司法》《中华人民共和国证券法》等法律、行政法规、 部门规章、规范性文件及《成都银行股份有限公司章程》的有关规定。 会议所形成的决议合法、有 ...

Summary of Key Points Core Viewpoint - The announcement details the completion of a share reduction plan by major shareholder Bai Ying, who reduced her stake in Aibo Medical from 4.95% to 2.95% through a series of block trades, totaling 3,862,700 shares, which represents 1.9972% of the company's total share capital [1][2]. Group 1: Shareholder Information - Bai Ying held 9,562,746 shares before the reduction, accounting for 4.95% of the total share capital [1]. - Bai Ying and her spouse, Mao Liping, are considered concerted actors, holding a combined total of 15,167,159 shares, which is 7.85% of the total shares [1][2]. Group 2: Reduction Plan Implementation - The reduction plan was first disclosed on June 4, 2025, and was executed between July 22 and September 3, 2025 [1]. - The shares were sold at prices ranging from 65.72 to 74.64 yuan per share, resulting in a total transaction amount of 276,823,762 yuan [1]. - The reduction was completed with only 62 shares remaining unsold, confirming that the plan was fully executed [1][2]. Group 3: Impact of the Reduction - The reduction does not trigger a mandatory tender offer, and the control structure of the company remains unchanged [1][2]. - Following the reduction, Bai Ying's shareholding decreased to 5,700,046 shares, or 2.95% of the total shares [1].

Core Viewpoint - The company has adjusted the maximum repurchase price of its shares from RMB 5 per share to RMB 7 per share to facilitate the smooth implementation of its share repurchase plan [1][2][3] Summary of Share Repurchase Plan - The company approved a share repurchase plan on June 23, 2025, with a total fund allocation of no less than RMB 60 million and no more than RMB 105.3 million, with an initial maximum repurchase price set at RMB 5 per share [1][2] - The repurchase period is set for a maximum of 12 months from the date of board approval [1] Implementation Status - As of the announcement date, the company has repurchased a total of 10 million shares, accounting for 0.35% of the total share capital, with a total transaction amount of RMB 47.202 million [2] Adjustment of Repurchase Price - The adjustment of the repurchase price was made due to the company's stock price consistently exceeding the original upper limit, ensuring the successful execution of the repurchase plan [2][3] - The new maximum repurchase price is set at RMB 7 per share, while the previous limit was RMB 5 per share [2][3] Impact of Price Adjustment - The adjustment is based on the company's recent stock performance and does not adversely affect its debt repayment ability or ongoing operations [3] - The company maintains that the adjustment will not harm the interests of the company or its shareholders [3][4] Decision-Making Process - The adjustment was approved by the sixth board of directors and the tenth supervisory board meeting, with independent directors expressing support for the decision [3][4] - The adjustment does not require further approval from the shareholders' meeting as it falls within the authority granted to the board [3] Compliance and Legality - The adjustment complies with relevant regulations and internal governance documents, ensuring that the decision-making process was legal and valid [4]

关于 2025 年第四次临时股东会增加临时提案暨股东会补 充通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 证券代码：000929 证券简称：*ST 兰黄 公告编号：2025（临）-66 兰州黄河企业股份有限公司 兰州黄河企业股份有限公司（以下简称"公司"）于 2025 年 9 月 3 日召开第十二届董事会第十三次会议审议通过了《关于召开 2025 年第四 次临时股东会的议案》，会议决定于 2025 年 9 月 25 日召开 2025 年第四 次临时股东会，并已于 2025 年 9 月 4 日在《中国证券报》《证券时报》 和巨潮资讯网（http://www.cninfo.com.cn）（以下简称"指定信息披露媒 体"）上刊登了《关于召开 2025 年第四次临时股东会的通知》（公告编 号：2025（临）-62）。 了《关于购买股权被动形成财务资助的议案》，该议案尚需提交公司股东 会审议。议案具体内容详见公司与本公告同日在指定信息披露媒体上刊登 （公告编号：2025（临）-65） （2）网络投票时间：2025 年 9 月 25 日。 的《关于购买股权被 ...

Core Viewpoint - Anhui Huaheng Biological Technology Co., Ltd. plans to issue H shares and list on the Hong Kong Stock Exchange to enhance its global development strategy, brand influence, and core competitiveness [1][2]. Meeting Details - The 18th meeting of the 4th Supervisory Board was held on September 4, 2025, with all three supervisors present, complying with relevant laws and regulations [1]. H Share Issuance Proposal - The Supervisory Board approved the proposal for issuing H shares and listing on the Hong Kong Stock Exchange, aiming to optimize capital structure and broaden financing channels [2][3]. - The H shares will be ordinary shares with a par value of RMB 1, issued in foreign currency [2]. Issuance and Listing Plan - The issuance will include both public offerings in Hong Kong and international placements, with the total number of H shares not exceeding 15% of the company's total share capital post-issuance [3][4]. - The final issuance price will be determined based on market conditions and investor demand [4]. Fund Utilization Plan - The funds raised from the H share issuance will be used for global expansion, new product development, capacity upgrades, and general corporate purposes [8][9]. Transition to Overseas Listed Company - Following the H share issuance, the company will transition to an overseas listed public company, listed on both the Shanghai Stock Exchange and the Hong Kong Stock Exchange [9]. Audit and Professional Services - The Supervisory Board approved the appointment of Yongcheng (Hong Kong) CPA Limited as the auditing firm for the H share issuance [10]. Governance Changes - The company plans to abolish the Supervisory Board and amend its Articles of Association to align with the latest legal requirements and improve governance structure [11].

成都银行股份有限公司独立董事关于第八届董事会 第十八次（临时）会议相关事项的独立意见 根据《中华人民共和国公司法》《上市公司治理准则》 《上市公司独立董事管理办法》《上海证券交易所股票上市 规则》《上海证券交易所上市公司自律监管指引第 1 号—— 规范运作》及《成都银行股份有限公司章程》 （以下简称"《公 司章程》"）等相关规定，作为成都银行股份有限公司（以 下简称"公司"）的独立董事，在认真审阅黄建军先生、Teoh Yih Min （张育鸣）先生的个人简历等资料并认真审查提名 程序、听取公司董事会说明的基础上，基于客观独立判断的 立场，就提名黄建军先生、张育鸣先生为第八届董事会非独 立董事候选人事宜发表如下独立意见： 一、本次黄建军先生、张育鸣先生的提名符合有关法律 法规及《公司章程》的要求，提名程序合法有效； 二、本次会议审议通过的《关于提名黄建军先生为成都 银行股份有限公司第八届董事会非独立董事候选人的议案》 《关于提名张育鸣先生为成都银行股份有限公司第八届董 事会非独立董事候选人的议案》审议、表决程序合法有效； 三、黄建军先生、张育鸣先生具备担任公司董事的条件 和资格，不存在法律、行政法规和部门规章及 ...

证券代码：605289 证券简称：罗曼股份 公告编号：2025-044 会议由监事会主席朱冰先生主持召开，会议以记名投票表决的方式，审议 通过了如下议案： 二、监事会会议审议情况： 议案》； 监事会认为：本次股权投资事项是基于合理的商业考虑，不存在损害公司 及 全 体股 东利 益的 情 形 。具 体 内容 详见 公司同 日在 上海 证 券交 易 所 网 站 （www.sse.com.cn）及指定媒体上披露的《关于购买资产暨关联交易的公告》 上海罗曼科技股份有限公司 第四届监事会第二十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况： 上海罗曼科技股份有限公司（以下简称"公司"）第四届监事会第二十六 次会议于2025年9月3日以现场结合通讯方式召开。会议通知及会议资料以书面 方式向全体监事发出。本次会议应出席监事3名，实际出席3名。本次会议的召 集和召开符合相关法律法规、《公司法》及《公司章程》的规定。 （公告编号：2025-042）。 议案表决情况：同意3票，反对0票，弃权0票。 监事会 ...